GlassScriptPhysician profile
Stephanie Ann Wilson
NPI 1386060929
$4,523.14
in general payments reported to CMS, 2019-2025
33 companies · $427 in 2025
The $427 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $840 · 2022: $624 · 2023: $769 · 2024: $1,862 · 2025: $427.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,059.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,058.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $556.00 | 2021-2025 | |
| Teva Pharmaceuticals USA, INC. | $398.06 | 2021-2024 | Austedo, Austedo Xr, Ajovy |
| Astrazeneca Pharmaceuticals LP | $357.27 | 2021 | |
| Sk Life Science, INC. | $261.06 | 2021-2025 | |
| Lundbeck LLC | $251.94 | 2023-2025 | Vyepti, Rexulti |
| Abbott Laboratories | $247.26 | 2022-2023 | Confirm Rx |
| Alexion Pharmaceuticals, INC. | $232.81 | 2023-2024 | Ultomiris |
| Pfizer INC. | $231.66 | 2023-2025 | |
| Novo Nordisk INC | $231.36 | 2021-2022 | |
| Ucb, INC. | $185.91 | 2023-2024 | Zilbrysq, Nayzilam, Briviact |
| Acadia Pharmaceuticals INC | $170.89 | 2024-2025 | Nuplazid |
| Novartis Pharmaceuticals Corporation | $163.63 | 2024-2025 | |
| Eisai INC. | $135.59 | 2023-2025 | |
| Scynexis, INC. | $130.48 | 2022 | |
| Mdd US Operations, LLC | $124.47 | 2023-2024 | Gocovri, Gocovri |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $95.24 | 2022 | |
| Tanabe Pharma America, INC. | $91.98 | 2024 | |
| Csl Behring | $82.69 | 2023-2024 | Hizentra |
| Acorda Therapeutics, INC | $72.89 | 2023-2024 | Inbrija |
| Amneal Pharmaceuticals LLC | $61.50 | 2023-2025 | Crexont, Rytary |
| Genentech USA, INC. | $50.63 | 2021-2024 | Ocrevus, Ocrevus Zunovo |
| Argenx US, INC. | $48.96 | 2024 | Vyvgart Hytrulo |
| Otsuka America Pharmaceutical, INC. | $46.68 | 2024 | Rexulti |
| Grifols USA, LLC | $36.90 | 2023-2024 | Gamunex-C |
| Mallinckrodt Hospital Products INC. | $36.71 | 2024 | Acthar |
| Lilly USA, LLC | $36.25 | 2023-2024 | Kisunla, Amyvid |
| Merz Pharmaceuticals, LLC | $33.31 | 2024 | Xeomin |
| Takeda Pharmaceuticals U.S.A., INC. | $28.21 | 2024 | Hyqvia |
| Octapharma USA, INC. | $27.73 | 2024 | Panzyga |
| Jazz Pharmaceuticals INC. | $26.60 | 2024 | |
| Cvrx, INC. | $24.03 | 2025 | Barostim Neo System |
| Azurity Pharmaceuticals, INC. | $23.91 | 2025 | |
| Scilex Pharmaceuticals INC. | $20.53 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephanie Wilson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.